RT Journal Article
SR Electronic
T1 Sulperazon-induced acute reactive thrombocytopenia during treatment of systemic lupus erythematosus: a case report
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP e18
OP e18
DO 10.1136/ejhpharm-2021-002999
VO 30
IS 4
A1 Lv, Mengen
A1 Xu, Qing
A1 Ye, Xianfei
A1 Yu, Qian
YR 2023
UL http://ejhp.bmj.com/content/30/4/e18.abstract
AB The purpose of this study is to report a patient who developed acute reactive thrombocytopenia while undergoing treatment with sulperazon for systemic lupus erythematosus (SLE). Sulperazon is a broad-spectrum antibiotic that can act against a wide range of microorganisms, but rarely causes severe thrombocytopenic events. We describe a 62-year-old man with new-onset acute reactive thrombocytopenia who experienced a precipitous fall in the platelet count from 168×109/L to 1×109/L within 29 hours after exposure to sulperazon. Sulperazon was immediately discontinued followed by administration of intravenous immunoglobulin for six consecutive days. The platelet count eventually recovered and petechiae at the injection sites improved. No complications secondary to acute reactive thrombocytopenia were observed except petechiae.All data relevant to the study are included in the article.